Status:

RECRUITING

Electroacupuncture Treatment for Post-stroke Cognitive Impairment

Lead Sponsor:

Ruijie Ma

Collaborating Sponsors:

Second Affiliated Hospital, School of Medicine, Zhejiang University

The Third Affiliated hospital of Zhejiang Chinese Medical University

Conditions:

Post-Stroke Cognitive Impairment (PSCI)

Eligibility:

All Genders

35-80 years

Phase:

NA

Brief Summary

Stroke is a global public health issue, and it has become a leading cause of death and disability in China. With the rapid aging of the Chinese population, its incidence rate is continuously rising. A...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • According to the Western diagnostic criteria for vascular cognitive impairment outlined in the "Chinese Guidelines for the Diagnosis and Treatment of Vascular Cognitive Impairment (2024 Edition)" developed by the Vascular Cognitive Impairment Branch of the Chinese Stroke Society.
  • Meets the traditional Chinese medicine diagnostic criteria for vascular cognitive impairment in the "Guidelines for Traditional Chinese Medicine Diagnosis and Treatment of Vascular Mild Cognitive Impairment (2024)";
  • The Mini Mental State Examination (MMSE) score ranges from 12-24, while the Montreal Cognitive Assessment (MoCA) score is below 24; Having cognitive impairment but not reaching the level of severe dementia; The National Institutes of Health Stroke Scale (NIHSS) score is ≤ 8 points; The Early Dementia Screening Scale (Ascertain Dementia 8, AD-8) score is less than 2 points;
  • Age between 35-80 years old;
  • Have basic communication skills, with Mandarin as the main language (communication language is sufficient), and have at least one stable caregiver;
  • Sign the informed consent form.
  • Exclusion criteria
  • Merge serious primary chronic diseases such as heart, liver, kidney, endocrine system, and hematopoietic system, as well as severe cardiovascular and cerebrovascular diseases;
  • Skin diseases or scar constitution such as herpes and ulceration are easy to appear on the body surface, which is not suitable for acupuncture and moxibustion treatment;
  • Not suitable for repetitive MRI examinations, such as claustrophobia, arterial aneurysm embolization, etc;
  • Patients with cognitive impairment or other severe neurological or mental disorders prior to the onset of this illness, and unstable control;
  • Patients identified by other clinical trial personnel as unsuitable for this study;
  • Participated in clinical research on related diseases in the past 3 months;

Exclusion

    Key Trial Info

    Start Date :

    October 5 2025

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    March 30 2027

    Estimated Enrollment :

    340 Patients enrolled

    Trial Details

    Trial ID

    NCT07208019

    Start Date

    October 5 2025

    End Date

    March 30 2027

    Last Update

    December 17 2025

    Active Locations (5)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (5 locations)

    1

    Zhejiang Provincial Hospital of Traditional Chinese Medicine

    Hangzhou, Zhejiang, China, 310006

    2

    Hangzhou Hospital of Traditional Chinese Medicine

    Hangzhou, Zhejiang, China, 310007

    3

    The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China, 310009

    4

    The Third Affiliated Hospital of Zhejiang Chinese Medical University

    Hangzhou, Zhejiang, China, 310053